Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;3(3):99-108.
doi: 10.1177/2042018812442949.

Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes

Dario Giugliano  1 , Katherine Esposito
Affiliations

Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes

Dario Giugliano et al. Ther Adv Endocrinol Metab. 2012 Jun.

Abstract

The three currently marketed long-acting insulin analogs, glargine, detemir and insulin lispro protamine suspension (ILPS), represent the most significant advances in basal insulin supplementation since the 1940s and 1950s and the introduction of the intermediate-acting NPH (neutral protamine Hagedorn) insulin. As injection of NPH insulin lacks chronic maintenance of a steady-state low-level basal insulin during fasting periods, which can also expose patients to unpredictable nocturnal hypoglycemia, long-acting insulin analogs have been developed to overcome this important limitation of NPH insulin. ILPS is a protamine-based, intermediate-acting insulin formulation of the short-acting analog insulin lispro: its pharmacokinetic and pharmacodynamic characteristics are quite similar to the other basal insulin analogs glargine and detemir. In recent head-to-head randomized controlled trials of insulin-naïve patients with type 2 diabetes, ILPS achieved similar glycemic control compared with glargine or detemir. ILPS administered once daily is an effective and safe way to maintain a steady-state low-level basal insulin during night time, not dissimilar from that currently obtained with a one-day glargine or detemir administration.

Keywords: ILPS (insulin lispro protamine suspension); detemir; glargine; long-acting insulin analogs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest in preparing this article

Figures

Figure 1.
Figure 1.
The short-acting insulin analog insulin lispro (LysB28, ProB29 human insulin) is formed by switching lysine and proline amino acids at positions B28 and B29.
See this image and copyright information in PMC

References

    1. American Diabetes Association (2012) Standards of medical care in diabetes - 2012. Diabetes Care 35(Suppl. 1): S11–S63 - PMC - PubMed
    1. Arakaki R.F., Blevins T.C., Liljenquist D.R., Wise J.K., Jiang H.H., Schneider K.K., et al. (2010) Efficacy and safety of insulin lispro protamine suspension (ILPS) versus insulin glargine (G) added to oral antihyperglycaemic medications and exenatide in patients with type 2 diabetes. Diabetologia 53(Suppl. 1): S556 (abstract).
    1. Bolli G.B., Di Marchi R.D., Park G.D., Proamming S., Koivisto V.A. (1999) Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42: 1151–1167 - PubMed
    1. Centers for Disease Control and Prevention (2007) Atlanta: 2007 National Diabetes Fact Sheet. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf
    1. Centers for Disease Control and Prevention (2009) Diabetes Data and Trends. http://www.cdc.gov/diabetes/statistics/complications_national.htm (accessed 4 February 2012).